Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Osteolysis 1Multiple Myeloma 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Epoetin Alfa 11Lenalidomide 5fludarabine phosphate 4Cyclosporine 4Cyclophosphamide 4fludarabine 3Filgrastim 3Darbepoetin alfa 3Busulfan 3Antilymphocyte Serum 3thymoglobulin 2Thiotepa 2Therapeutics 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Ferric Oxide, Saccharated 2Biopsy 2AP 1903 reagent 2venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1obinutuzumab 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × ARQ 197 × Other hematologic neoplasm × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡